A Mid-September Biotech Update
Research - What a crazy end of summer. Thankfully, today’s the first day of Fall. We’ve got a bunch of updates – insights and administrative – for … Continue Reading
Premium: Read NowzPremium
uniQure’s First AMT-110 Gene Therapy Results Encouraging
Research - Over the weekend, the scientific and investing communities had a first look at 1-year follow-up results for AMT-110, uniQure’s (QURE) gene therapy candidate for the treatment of Sanfilippo B.
Read Now
A September Market Update
Research - Last week was yet another exhausting, anemic few sessions in the markets. One day we're up, and the next we're down - with gaps nonetheless - but a trend is non-existent.
Premium: Read Now
Esperion’s Meeting with the FDA Went Quite Well
Research - FDA confirms that LDL-C remains a viable surrogate endpoint for cholesterol-lowering drugs. ETC-1002 does not need a cardiovascular outcomes study prior to approval, and -1002 should be … Continue Reading
Premium: Read Now
Coming Away From Second Quarter Earnings, Here’s What’s New in Biotech
Research - It’s been “risk-off” in equities this week as traders begin to factor in a rate hike from the Fed, and the high-beta biotech sector has … Continue Reading
Read Now
Revisiting Two of Our Early ’15 Biotech Ideas
Research - On Affimed's trial delay and Marinus' three-month performance.
Premium: Read Now
Drug Profile Confirmed, Synergy’s Plecanatide Looks Better Than Ever
Research - Second phase III trial confirms drug profile of plecanatide, allaying any fears that the low diarrhea rate in the first phase III was a fluke. With … Continue Reading
Premium: Read Now